Hippocampal volume changes in a pharmacological sex-hormone manipulation risk model for depression in women

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Hippocampal volume changes in a pharmacological sex-hormone manipulation risk model for depression in women. / Borgsted, Camilla; Hoegsted, Emma; Henningsson, Susanne; Pinborg, Anja; Ganz, Melanie; Frokjaer, Vibe G.

In: Hormones and Behavior, Vol. 145, 105234, 2022.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Borgsted, C, Hoegsted, E, Henningsson, S, Pinborg, A, Ganz, M & Frokjaer, VG 2022, 'Hippocampal volume changes in a pharmacological sex-hormone manipulation risk model for depression in women', Hormones and Behavior, vol. 145, 105234. https://doi.org/10.1016/j.yhbeh.2022.105234

APA

Borgsted, C., Hoegsted, E., Henningsson, S., Pinborg, A., Ganz, M., & Frokjaer, V. G. (2022). Hippocampal volume changes in a pharmacological sex-hormone manipulation risk model for depression in women. Hormones and Behavior, 145, [105234]. https://doi.org/10.1016/j.yhbeh.2022.105234

Vancouver

Borgsted C, Hoegsted E, Henningsson S, Pinborg A, Ganz M, Frokjaer VG. Hippocampal volume changes in a pharmacological sex-hormone manipulation risk model for depression in women. Hormones and Behavior. 2022;145. 105234. https://doi.org/10.1016/j.yhbeh.2022.105234

Author

Borgsted, Camilla ; Hoegsted, Emma ; Henningsson, Susanne ; Pinborg, Anja ; Ganz, Melanie ; Frokjaer, Vibe G. / Hippocampal volume changes in a pharmacological sex-hormone manipulation risk model for depression in women. In: Hormones and Behavior. 2022 ; Vol. 145.

Bibtex

@article{dde9f45635ba483ca88d6c9f3d7b91de,
title = "Hippocampal volume changes in a pharmacological sex-hormone manipulation risk model for depression in women",
abstract = "Hormone transition phases may trigger depression in some women, yet the underlying mechanisms remain elusive. In a pharmacological sex-hormone manipulation model, we previously reported that estradiol reductions, induced with a gonadotropin-releasing hormone agonist (GnRHa), provoked subclinical depressive symptoms in healthy women, especially if neocortical serotonin transporter (SERT) binding also increased. Within this model, we here evaluated if GnRHa, compared to placebo, reduced hippocampal volume, in a manner that depended on the magnitude of the estradiol decrease and SERT binding, and if this decrease translated to the emergence of subclinical depressive symptoms. Sixty-three healthy, naturally cycling women were included in a randomized, double-blind, placebo-controlled GnRHa-intervention study. We quantified the change from baseline to follow-up (n = 60) in serum estradiol (ΔEstradiol), neocortical SERT binding ([ 11C] DASB positron emission tomography; ΔSERT), subclinical depressive symptoms (Hamilton depression rating scale; ΔHAMD-17), and hippocampal volume (magnetic resonance imaging data analyzed in Freesurfer 7.1, ΔHippocampus). Group differences in ΔHippocampus were evaluated in a t-test. Within the GnRHa group, associations between ΔEstradiol, ΔHippocampus, and ΔHAMD-17, in addition to ΔSERT-by-ΔEstradiol interaction effects on ΔHippocampus, were evaluated with linear regression models. Mean ΔHippocampus was not significantly different between the GnRHa and placebo group. Within the GnRHa group, hippocampal volume reductions were associated with the magnitude of estradiol decrease (p = 0.04, Cohen's f 2 = 0.18), controlled for baseline SERT binding, but not subclinical depressive symptoms. There was no ΔSERT-by-ΔEstradiol interaction effects on ΔHippocampus. If replicated, our data highlight a possible association between estradiol fluctuations and hippocampal plasticity, adjusted for serotonergic contributions. ",
author = "Camilla Borgsted and Emma Hoegsted and Susanne Henningsson and Anja Pinborg and Melanie Ganz and Frokjaer, {Vibe G}",
note = "Copyright {\textcopyright} 2022. Published by Elsevier Inc.",
year = "2022",
doi = "10.1016/j.yhbeh.2022.105234",
language = "English",
volume = "145",
journal = "Hormones and Behavior",
issn = "0018-506X",
publisher = "Academic Press",

}

RIS

TY - JOUR

T1 - Hippocampal volume changes in a pharmacological sex-hormone manipulation risk model for depression in women

AU - Borgsted, Camilla

AU - Hoegsted, Emma

AU - Henningsson, Susanne

AU - Pinborg, Anja

AU - Ganz, Melanie

AU - Frokjaer, Vibe G

N1 - Copyright © 2022. Published by Elsevier Inc.

PY - 2022

Y1 - 2022

N2 - Hormone transition phases may trigger depression in some women, yet the underlying mechanisms remain elusive. In a pharmacological sex-hormone manipulation model, we previously reported that estradiol reductions, induced with a gonadotropin-releasing hormone agonist (GnRHa), provoked subclinical depressive symptoms in healthy women, especially if neocortical serotonin transporter (SERT) binding also increased. Within this model, we here evaluated if GnRHa, compared to placebo, reduced hippocampal volume, in a manner that depended on the magnitude of the estradiol decrease and SERT binding, and if this decrease translated to the emergence of subclinical depressive symptoms. Sixty-three healthy, naturally cycling women were included in a randomized, double-blind, placebo-controlled GnRHa-intervention study. We quantified the change from baseline to follow-up (n = 60) in serum estradiol (ΔEstradiol), neocortical SERT binding ([ 11C] DASB positron emission tomography; ΔSERT), subclinical depressive symptoms (Hamilton depression rating scale; ΔHAMD-17), and hippocampal volume (magnetic resonance imaging data analyzed in Freesurfer 7.1, ΔHippocampus). Group differences in ΔHippocampus were evaluated in a t-test. Within the GnRHa group, associations between ΔEstradiol, ΔHippocampus, and ΔHAMD-17, in addition to ΔSERT-by-ΔEstradiol interaction effects on ΔHippocampus, were evaluated with linear regression models. Mean ΔHippocampus was not significantly different between the GnRHa and placebo group. Within the GnRHa group, hippocampal volume reductions were associated with the magnitude of estradiol decrease (p = 0.04, Cohen's f 2 = 0.18), controlled for baseline SERT binding, but not subclinical depressive symptoms. There was no ΔSERT-by-ΔEstradiol interaction effects on ΔHippocampus. If replicated, our data highlight a possible association between estradiol fluctuations and hippocampal plasticity, adjusted for serotonergic contributions.

AB - Hormone transition phases may trigger depression in some women, yet the underlying mechanisms remain elusive. In a pharmacological sex-hormone manipulation model, we previously reported that estradiol reductions, induced with a gonadotropin-releasing hormone agonist (GnRHa), provoked subclinical depressive symptoms in healthy women, especially if neocortical serotonin transporter (SERT) binding also increased. Within this model, we here evaluated if GnRHa, compared to placebo, reduced hippocampal volume, in a manner that depended on the magnitude of the estradiol decrease and SERT binding, and if this decrease translated to the emergence of subclinical depressive symptoms. Sixty-three healthy, naturally cycling women were included in a randomized, double-blind, placebo-controlled GnRHa-intervention study. We quantified the change from baseline to follow-up (n = 60) in serum estradiol (ΔEstradiol), neocortical SERT binding ([ 11C] DASB positron emission tomography; ΔSERT), subclinical depressive symptoms (Hamilton depression rating scale; ΔHAMD-17), and hippocampal volume (magnetic resonance imaging data analyzed in Freesurfer 7.1, ΔHippocampus). Group differences in ΔHippocampus were evaluated in a t-test. Within the GnRHa group, associations between ΔEstradiol, ΔHippocampus, and ΔHAMD-17, in addition to ΔSERT-by-ΔEstradiol interaction effects on ΔHippocampus, were evaluated with linear regression models. Mean ΔHippocampus was not significantly different between the GnRHa and placebo group. Within the GnRHa group, hippocampal volume reductions were associated with the magnitude of estradiol decrease (p = 0.04, Cohen's f 2 = 0.18), controlled for baseline SERT binding, but not subclinical depressive symptoms. There was no ΔSERT-by-ΔEstradiol interaction effects on ΔHippocampus. If replicated, our data highlight a possible association between estradiol fluctuations and hippocampal plasticity, adjusted for serotonergic contributions.

U2 - 10.1016/j.yhbeh.2022.105234

DO - 10.1016/j.yhbeh.2022.105234

M3 - Journal article

C2 - 35905507

VL - 145

JO - Hormones and Behavior

JF - Hormones and Behavior

SN - 0018-506X

M1 - 105234

ER -

ID: 315757733